Kinder Morgan Inc vs Merck & Co., Inc. — how do they compare? Kinder Morgan Inc trades at $31.46 (market cap $70.10B), while Merck & Co., Inc. trades at $129.52 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 4.6× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| KMI | MRK | |
|---|---|---|
Market Cap | $70.10B | $321.77B |
Sector | Energy | Health |
52-Week High | $34.31 | $131.84 |
52-Week Low | $25.84 | $77.60 |
Enterprise Value | $102.15B | $368.53B |
Dividend Yield | 3.75% | 2.61% |
Signals from Pluang's Aura AI — not financial advice
KMI trades at $31.39, up 1.75% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 19.31% net income margin. Recent news highlights a $5 billion Western Gateway Pipeline joint venture with Phillips 66 and HF Sinclair, signaling growth in energy infrastructure.
The outlook is mixed: robust cash flow and dividend sustainability support income investors, but high debt levels and bearish technical indicators pose risks. Analyst consensus is nearly split between Buy and Hold, reflecting cautious optimism amid valuation concerns.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →